Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortization of Deferred ChargesAmortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kura Oncology (KURA) Change in Accured Expenses (2023 - 2026)

Kura Oncology has reported Change in Accured Expenses over the past 4 years, most recently at -$16.2 million for Q1 2026.

  • Quarterly Change in Accured Expenses fell 88.25% to -$16.2 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $5.1 million through Mar 2026, down 55.45% year-over-year, with the annual reading at $12.7 million for FY2025, 24.8% down from the prior year.
  • Change in Accured Expenses was -$16.2 million for Q1 2026 at Kura Oncology, down from -$2.2 million in the prior quarter.
  • Over five years, Change in Accured Expenses peaked at $14.3 million in Q4 2024 and troughed at -$16.2 million in Q1 2026.
  • The 4-year median for Change in Accured Expenses is $3.9 million (2023), against an average of $1.9 million.
  • The largest YoY upside for Change in Accured Expenses was 21524.0% in 2025 against a maximum downside of 175.38% in 2025.
  • A 4-year view of Change in Accured Expenses shows it stood at $8.6 million in 2023, then soared by 67.2% to $14.3 million in 2024, then crashed by 115.07% to -$2.2 million in 2025, then tumbled by 650.74% to -$16.2 million in 2026.
  • Per Business Quant, the three most recent readings for KURA's Change in Accured Expenses are -$16.2 million (Q1 2026), -$2.2 million (Q4 2025), and $12.7 million (Q3 2025).